Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01233232 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01233232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01233232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
March 31, 2011
Enrollment
109 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

laymen terminology chronic bronchitis and emphysema, scientific terminology chronic obstructive pulmonary disease (copd)